Conductive keratoplasty to correct residual hyperopia after corneal surgery.

Conductive keratoplasty (CK) is an electrical-current-based technique for steepening the central cornea to reduce low to moderate hyperopia. We report 4 patients who had CK to correct hyperopia after laser in situ keratomileusis (LASIK) and were followed for at least 6 months. An overcorrection was noted after the CK procedure in all patients, but no sight-threatening complications arose.

Progressive post-LASIK keratectasia: biomechanical instability or chronic disease process?

Progressive post-LASIK keratectasia (PPLK) is a progressive deformation of corneal anatomy that occurs rarely but may have severe consequences. Using the scientific literature and new hypotheses, we attempted to determine whether PPLK is a biomechanical result of laser in situ keratomileusis (LASIK), a chronic disease process affecting individuals predisposed to the condition, or a combination of processes. We look at whether the combination of fatigue, specifically a form of dynamic fatigue, and proteolysis provides an environment conducive to the occurrence and progression of PPLK.

Patients treated with vigabatrin exhibit central visual function loss.

Purpose: To investigate visual function in the central 10 degrees in patients who have undergone vigabatrin (VGB) antiepileptic drug (AED) therapy with the aim of identifying a clinical regimen for assessing central visual function.

Methods: The sample comprised 12 epilepsy patients (mean age, 38.6 +/- 11.

Laser in situ keratomileusis for residual myopia after photorefractive keratectomy.

Purpose: To evaluate the efficacy and safety of laser in situ keratomileusis (LASIK) for myopic regression and undercorrection after photorefractive keratectomy (PRK).

Setting: The Eye Institute, Sydney, Australia.

Methods: Fifty eyes of 32 patients were treated by LASIK for residual myopia following primary PRK.

Phakic intraocular lenses.

Since Zaldivar's review of phakic intraocular lenses in these pages in 2000 [1**], further reports of experience with this technology have emerged. Their relative advantages and disadvantages over competing technologies are becoming clearer. Clinical trials, including Food & Drug Administration (FDA) trials, have shown predictability, stability, and efficacy.